Should you run Vesugen or Chonluten

Vesugen has two published papers behind it and Chonluten has one, and that gap decides most of the vesugen vs chonluten question. Short answer: run Vesugen if you want a vascular-focused Khavinson peptide with at least some human data, and treat Chonluten as a lower-confidence option for lung and airway support.

Both come from the Khavinson short-peptide family, a group of two-to-four amino acid chains developed in Russia and proposed to act on gene expression in specific tissues. I see people lump them together because the dosing conventions are identical, but the evidence behind each is very different, and that is the first thing worth sorting out before you spend money.

Evidence quality

Vesugen is a tripeptide (three amino acids: lysine, glutamic acid, aspartic acid) aimed at the lining of blood vessels. Its best animal work is a mouse study in a severe Alzheimer's model, where daily injections for two months restored the density of the mature spines on hippocampal neurons to control levels. That is a brain finding in a transgenic mouse, so it says little about vascular outcomes in a person. The paper also carries a correction notice because two figures were identical but described differently. The authors say the conclusions are unaffected, but you should know the correction exists.

The human data is a cohort of 32 older patients with multiple chronic conditions, where Vesugen was reported to slow biological-age markers and did better than the comparison peptide, Pinealon. It was unblinded, small and run at a single site. I treat it as a reason to be curious and a weak reason to expect a particular result.

Chonluten has less. The only citation is a cell-line experiment in which a group of peptides, Chonluten among them, shifted proliferation and inflammatory signaling (TNF and IL-6, two inflammation messengers) in a monocyte-macrophage line. No animal study isolates Chonluten, and no human study exists at all. Anything you hear about it repairing lung tissue is extrapolation from the family's general claims.

On evidence alone, Vesugen wins clearly, though both sit at the low end of the scale. You can read the full entries for Vesugen and Chonluten for the details I am not repeating here.

Cost and side-effect load

Cost is close to a tie, because the dosing convention is the same. A course is 10 to 20 days, so you buy a small amount of powder per cycle, and neither compound needs a long continuous supply. Prices vary by vendor and batch, so compare cost per milligram on a tested product and not on the sticker price of the vial. Running both doubles the spend for a pair with no published combination data, which is a real consideration if you are on a budget.

Side effects are also close to a tie. Neither has a documented serious adverse event, and the reported family-wide profile is mild: occasional irritation at the injection site and a transient headache early in a course. That profile is based on thin Russian-literature reporting, so the absence of reported harm is not the same as a safety study. For Chonluten there is no adverse-event data specific to the compound at all.

The practical risk I would weigh more heavily is the supply chain. Khavinson-family peptides are the most counterfeited category in the gray market, and a thin published record makes mislabeling easy to get away with because there is little independent literature to check a seller's claims against. If you go ahead with either one, read the certificate of analysis first, and my guide on how to read a peptide certificate of analysis walks through what to look for.

Who each one actually suits

Vesugen suits you if your goal is vascular and healthy-aging support and you are comfortable with an experiment backed by small studies. It is also the more sensible starting point if you are choosing a single Khavinson peptide to learn how you respond. If you are weighing it against a different organ-targeted peptide, the comparison with Vesugen and Bronchogen covers a similar decision.

Chonluten suits a narrower person: someone who wants to try a respiratory-focused Khavinson peptide, accepts that nothing beyond a cell experiment supports it, and has already handled the basics for lung health, such as air quality, sleep and not smoking. I have clients who ask about it for chronic airway irritation, and my answer is that it is a low-cost experiment at best and should never replace seeing a physician about a cough or breathing problem that persists.

If you want to run only one, I would run Vesugen. If you run both, do them in separate courses so you can tell which one, if either, is changing anything for you.

What people actually run

In the mouse work the dose was 400 mcg per kilogram injected daily, which does not convert cleanly to a human subcutaneous dose. The real-world protocol most people follow for both peptides is about 100 to 200 mcg per day by subcutaneous injection for 10 to 20 consecutive days, repeated 2 to 3 times per year. That number comes from community and Russian-school convention and has not been validated for either compound in a dose-finding trial. Once reconstituted, keep the vial refrigerated and use it within roughly 28 days.

Before you write any of this down, the obligatory: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

My own position on both is that I try to stay evidence-based with peptides, and for the Khavinson family that means saying the evidence is early and giving you the practical information anyway. Vesugen has enough to justify a careful trial run, Chonluten has enough to justify curiosity, and neither replaces the sleep, nutrition and movement work that determines how long any result lasts.

Thanks for reading! In health, Rick Gold